Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.61 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL713213 | 1.00 | LTA4H (0.62) | LTA4HCYP3A4SLC7A5NLN | |
| Hydrochloric Acid SCHEMBL27320108 | 0.99 | LTA4H (0.61) | LTA4HCYP3A4SLC7A5 | |
| SCHEMBL6816189 | 0.90 | LTA4H (0.58) | LTA4HCYP3A4SLC7A5NLN | |
| SCHEMBL3626018 | 0.87 | CYP3A4 (0.58) | LTA4HCYP3A4SLC7A5NLN | |
| SCHEMBL1007042 | 0.87 | CYP3A4 (0.61) | LTA4HCYP3A4SLC7A5NLN | |
| SCHEMBL21001107 | 0.84 | CYP3A4 (0.51) | LTA4HCYP3A4SLC7A5NLN | |
| SCHEMBL28231837 | 0.84 | CYP3A4 (0.57) | LTA4HCYP3A4SLC7A5NLN | |
| SCHEMBL11416854 | 0.83 | CYP3A4 (0.50) | LTA4HCYP3A4SLC7A5NLN | |
| SCHEMBL6114085 | 0.83 | CYP3A4 (0.62) | LTA4HCYP3A4SLC7A5NLN | |
| Phenylalanine SCHEMBL28074950 | 0.82 | SLC7A5 (0.80) | LTA4HCYP3A4SLC7A5NLN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324131-A1 | Salvinorin Derivatives and Uses Thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2010-12-23 | — | — | US | disclosed |
| US-7629475-B2 | Salvinorin derivatives and uses thereof | THE MCLEAN HOSPITAL CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-20070213394-A1 | Salvinorin derivatives and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324131-A1 | Salvinorin Derivatives and Uses Thereof | OPRK1, OPRD1, OPRM1 | LTA4H 3671/4885CYP3A4 1293/4885SLC7A5 1581/4885 |
| US-20070213394-A1 | Salvinorin derivatives and uses thereof | OPRK1, OPRD1, OPRM1 | LTA4H 3671/4885CYP3A4 1293/4885SLC7A5 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.